BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30836365)

  • 1. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
    Wu X; Li J; Zhou Y; Mao Y; Luo S; He X; Wang L; Shen Y; Zhang H; Yang L; Zhang J
    Chemotherapy; 2018; 63(6):301-307. PubMed ID: 30836365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
    Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
    Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
    Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
    Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
    Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level.
    Wu X; Ge Y; He X; Li J; Zhang J
    Front Surg; 2023; 10():1115141. PubMed ID: 36911619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning.
    Ran P; Tan T; Li J; Yang H; Li J; Zhang J
    BMC Cancer; 2024 Feb; 24(1):264. PubMed ID: 38402382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
    Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
    Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
    Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
    Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
    Yin Y; Xiang J; Tang S; Chen J; Yu Q; Zhang B
    Medicine (Baltimore); 2016 Dec; 95(49):e5488. PubMed ID: 27930532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
    Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
    Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
    Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
    Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
    Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
    Chen H; Liu J; Zhou Y; Hou Y; Ma G; Cai W
    Ther Drug Monit; 2019 Oct; 41(5):582-590. PubMed ID: 31045869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
    IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
    Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
    Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
    J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.
    Tjhoi WEH; Li K; Shou CH; Yang WL; Yu JR
    Medicine (Baltimore); 2019 Feb; 98(6):e14477. PubMed ID: 30732216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.